Eric Geller, MD
Neurology · Livingston, NJNPI 1780788992
Payments from drug & device makers
Across 112 payments — averaging $53.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuropace, Inc.$4K
- AbbVie$247
- Livanova USA, Inc.$210
- SK Life Science, Inc.$175
- Amgen$140
- Novartis$91
- plus $954 from 24 others
What the payments were for
- Consulting fees$2,80047%
- Travel & lodging$57210%
- Food & beverage$2,59543%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuropace, Inc. | 13 | $4,150 |
| AbbVie | 16 | $247 |
| Livanova USA, Inc. | 10 | $210 |
| SK Life Science, Inc. | 9 | $175 |
| Amgen | 4 | $140 |
| Novartis | 5 | $91 |
| Pfizer | 5 | $91 |
| Corium, LLC | 4 | $87 |
| UCB, Inc. | 4 | $77 |
| Pyros Pharmaceuticals, Inc. | 1 | $65 |
| Harmony Biosciences LLC | 4 | $62 |
| Aquestive Therapeutics, Inc. | 4 | $59 |
| Supernus Pharmaceuticals, Inc. | 4 | $58 |
| Jazz Pharmaceuticals Inc. | 3 | $52 |
| Medtronic | 1 | $46 |
| Sunovion Pharmaceuticals Inc. | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $42 |
| Aucta Pharmaceuticals, Inc. | 4 | $39 |
| Immedica Pharma US, Inc. | 2 | $30 |
| Ironshore Pharmaceuticals Inc. | 2 | $29 |
| Acadia Pharmaceuticals Inc | 2 | $26 |
| Lilly USA, LLC | 2 | $26 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $18 |
| Nobelpharma America, LLC | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi | 1 | $14 |
| Greenwich Biosciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RNS System$3,801
- RNS Neurostimulator Kit$117
How this compares
$5,968 in reported general payments places this provider in the 60th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 266 | $377,764 |
| BriviactBrivaracetam | 172 | $341,277 |
| BanzelRufinamide | 28 | $210,323 |
| EpidiolexCannabidiol (Cbd) | 76 | $208,726 |
| AptiomEslicarbazepine Acetate | 106 | $187,056 |
| LamictalLamotrigine | 110 | $183,525 |
| Lamictal XrLamotrigine | 72 | $176,218 |
| ZonegranZonisamide | 21 | $128,550 |
| FycompaPerampanel | 75 | $95,267 |
| VimpatLacosamide | 93 | $94,973 |
| Lamotrigine ErLamotrigine | 164 | $73,898 |
| FelbatolFelbamate | 18 | $67,269 |
| KeppraLevetiracetam | 36 | $55,503 |
| Keppra XrLevetiracetam | 21 | $52,464 |
| NayzilamMidazolam | 59 | $52,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat, Nayzilam | $77 | $488,512324 claims |
| SK Life Science, Inc.Xcopri | $175 | $377,764266 claims |
| Eisai Inc.Banzel, Fycompa | $15 | $305,590103 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $43 | $187,056106 claims |
| Aquestive Therapeutics, Inc.Sympazan | $59 | $30,48211 claims |
| PfizerLyrica, Dilantin | $91 | $25,88878 claims |
| Aucta Pharmaceuticals, Inc.Motpoly Xr | $39 | $24,98621 claims |
| AbbVieQulipta | $247 | $16,38315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 521 neurology providers in New Jersey.
Other neurology in Livingston
- Matthew TremblayLivingston$812K
- Sami SabaLivingston$127K
- Mangala NadkarniLivingston$72K
- Mary Ann PiconeTeaneck$2.8M
- Steven BromleyAudubon$1.7M
- David DuncanNeptune$1.5M
- Lana Zhovtis RyersonNeptune$1.3M
- Amos KatzEatontown$1.2M
- Fiona GuptaOradell$1.1M
- Andrew SylvesterBridgewater$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.